Fresenius Kabi has acquired Ivenix, Inc., a medical technology company that specialises in cutting-edge infusion systems
In March 2022, Ivenix, Inc., a medical technology business that specialises in cutting-edge infusion systems, has been bought by Fresenius Kabi, according to a company announcement. This contributes to quickening the market expansion for infusion therapy, which is a significant and expanding segment of the biopharmaceuticals and medical technology sectors.
Advancement of Technology to Accelerate Market Growth
The impact of technological improvements on clinical services and healthcare is being expanded and made more available. The use of an ambulatory infusion pump has benefited from technological advancements that reduce patient harm and prevent drug errors. With the use of a patient monitoring device to inform and direct clinicians' treatment decisions, these developments lead to better clinical outcomes. Nearly every process in the healthcare sector involves the use of technology, including patient registration for data management, laboratory testing for self-care equipment, the possibility of medication errors due to an increase in disease burden, and infusion pump systems, accessories, and software. This is why technology is the next growth driver in this sector. The development of technologies has several benefits for improving the effectiveness of procedures, which increases patient safety. As a result, expanding technical improvements are anticipated to fuel the global market for ambulatory infusion pumps.
Side Effects from Ambulatory Infusion Pumps Could Impede Growth
With the development of technology, hospitals now routinely employ ambulatory infusion pumps to give patients the vital fluids they need. Unfortunately, there are still few research studies for minimising mistakes and enhancing the usage of ambulatory infusion pumps that result in unfavourable systemic consequences. Its many issues can be caused by either software bugs or human faults. Software issues, poor user interface design, broken components, battery failures, alarm faults, and charring or shocks are some of the negative effects of ambulatory infusion pump systems.
Major Players Develop Acquisition Plans to Boost Brand Image
The leading businesses in the ambulatory infusion pumps market plan acquisitions to improve their brand recognition globally. For instance, in February 2022, the Plum 360 Infusion System from ICU Medical, Inc., which is a top-performing smart pump with EMR integration, has once again been recognised as best in KLAS. This Best in KLAS designation is the result of thorough side-by-side comparisons of IV smart pump performance in a number of categories, including culture, loyalty, operations, product, relationship, and value. It is based on feedback from thousands of healthcare providers across the United States and Canada.
List of Key Players Profiled in the Report
- B. Braun Melsungen AG
- Moog, Inc.
- KORU Medical Systems
- Intra Pump Infusion Systems
- ICU Medical, Inc.
- Eitan Medical
- Fresenius Kabi (a subsidiary of Fresenius SE & Co. KGaA)
- Medtronic, Micrel Medical Devices
- The market in North America is expected to gain a huge portion of the global Ambulatory infusion pumps market share in the coming years attributable to the infusion pumps system's ongoing technological improvements.
- Due to the high frequency of numerous chronic and acute illnesses among Americans, the U.S. is anticipated to dominate the market.
- In the Asia Pacific, the growth in this region is primarily driven by an established healthcare system and the existence of major market participants for infusion pumps.
|Market Size in 2022
|USD 1.5 Billion
|Market Forecast in 2030
|USD 2.4 Billion
|Compound Annual Growth Rate
|Revenue (USD Million) and Volume (Kilo Tons)
|By Product Type, By Usage, By Route of Administration, By Application, By End Users, By Distribution Channel and By Geography
|By Product Type
|By Route of Administration
|By End Users
|By Distribution Channel